icon-folder.gif   Conference Reports for NATAP  
The Liver Meeting
Boston MA
November 2016
Back grey_arrow_rt.gif
Ledipasvir/Sofosbuvir in Egyptian Patients With Chronic Genotype 4 HCV Infection
  Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Gamal Shiha,1 Imam Waked,2 Reham El-Sayed Soliman,1 Wael Abdelrazek,2 Mohamed Hassany,3 Rabab Fouad,4 Waleed Samir,1 Talaat Zakareya,2 Radi Hammad,3
Sherief Musa,4 Kathryn Kersey,5 Sophia Lu,5 Benedetta Massetto,5 Diana M. Brainard,5 John G. McHutchison,5 Wahid Doss,3 Gamal Esmat4
1Egyptian Liver Research Institute and Hospital, Mansoura, Egypt; 2National Liver Institute-Menoufia University, Menoufia, Egypt; 3National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt; 4Cairo University, Giza, Egypt; 5Gilead Sciences, Inc., Foster City, CA
AASLD: Integrated Analysis of Sofosbuvir +Ribavirin, Ledipasvir/Sofosbuvir or Sofosbuvir/Velpatasvir for the Treatment of Genotype 4 Chronic HCV Infection - (11/15/16)
AASLD: Six weeks of sofosbuvir/ledipasvir treatment of acute hepatitis C virus genotype 1 mono-infection: Final results of The German HepNet Acute HCV IV Study......55% were sexual transmission including 5 MSM - (11/17/16)